A randomized discontinuation trial to determine the clinical benefit of continuation of sorafenib following disease progression in patients with advanced renal cell carcinoma.
Phase of Trial: Phase IV
Latest Information Update: 08 Jan 2015
At a glance
- Drugs Gemcitabine; Interferon; Sorafenib
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms PROGRESS
- Sponsors Bayer
- 01 Apr 2009 Planned end date added as 1 Nov 2006 as reported by ClinicalTrisl.gov.
- 14 Jul 2007 New trial record.